



#### Disclaimer



The materials being provided to you in connection with this presentation are strictly confidential and intended only for informational purposes and convenient reference.

This document has been prepared by Ilika plc ("Ilika") and is the responsibility of the same and comprises the written materials for a presentation to investors concerning Ilika.

This information is not intended to provide, and should not be relied upon, for accounting, legal, tax advice or investment recommendations. You should consult your tax, legal, accounting or other professional advisors about the issues discussed herein. The descriptions contained herein are summaries and are not intended to be complete and neither llika nor any of its subsidiaries or affiliates undertakes any obligation to update or correct any errors or inaccuracies in any of the information presented herein. The information in these materials and any other information discussed at the presentation is subject to change.

These materials do not constitute or form part of any offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities of llika in any jurisdiction, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or investment decision in relation thereto.

The distribution of these materials in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession these materials come should inform themselves about and observe any relevant restrictions. In particular, these materials are not for publication or distribution, directly or indirectly, in, into or from the United States of America, Canada, Australia, the Republic of South Africa or Japan. Any failure to comply with the above restrictions may constitute a violation of such securities laws.

Ilika has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended (the "Investment Company Act") and the holders of its shares will not be entitled to the benefits of that Arise and sale of the shares mentioned herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act of 1934, as amended of the U.S. persons. In connection with the transaction referred to in this presentation the shares of lilka will be offered and sold only outside the United States to no U.S. persons in "offshore transactions" within the meaning of, and in reliance on the exemption from registration provided by Regulation S under the Securities Act. No public offer of the shares is being made in the United States and the information contained herein does not constitute an offering of securities for sale in the United States, Canada, Australia, South Africa, the Republic of Ireland or Japan. No money, securities or other consideration is being solicited and, if sent in response to the information contained herein, will not be accepted. Any failure to comply with the above restrictions may constitute a violation of such securities laws.

Neither Ilika nor any of its subsidiaries or affiliates makes any representation or warranty, express or implied as to the accuracy, completeness or verification of the information contained herein, and nothing contained herein shall be relied upon as a promise or representation whether as to past or future performance. In giving this presentation, neither Ilika nor its respective advisers and/or agents undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.

This material is confidential and distribution of this material to any person other than the person to whom this information was originally delivered and to such person's advisors is unauthorised and any reproduction or redistribution of these materials, in whole or in part, or the disclosure of any of their contents, without the prior consent of llika or its affiliates is prohibited.

These materials and any offer mentioned herein if subsequently made are only addressed to and directed at persons in member states of the European Economic Area who are 'qualified investors' within the meaning of Article (2)(1)(e) of the Prospectus Directive (Directive 2003/71/EC). This document is for distribution in the United Kingdom only to persons who are authorised or exempt persons within the meaning of the Financial Services and Markets Act 2000 or the Financial Promotion or exempt persons within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, (all such persons together being referred to as, "relevant persons"). This document is directed only at relevant persons. Other persons should not act or rely on this document or any of its contents. Any investment or investment activity to which this presentation relates is available only to (i) in the United Kingdom, Relevant Persons and (ii) in any member state of the EEA other than the United Kingdom, and will be engaged in only with such persons. Solicitations resulting from this presentation will only be responded to if the person concerned is, (i) in the United Kingdom, a Relevant Person, and (ii) in any member state of the EEA other than the United Kingdom, a Qualified Investor.

These materials include statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. In some cases, these forward-looking statements may be identified by the use of forward-looking terminalogy, including the terms "estimates" "estimates

These materials include statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. In some cases, these forward-looking statements may be identified by the use of forward-looking terminology, including the terms "targets", "believes", "estimates", "anticipates", expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. They appear in a number of places throughout these materials and include statements regarding the intentions, beliefs or current expectations of llika and/or its directors concerning, among other things, the rading performance, results of operations, financial condition, liquidity, prospects and dividend policy of Ilika. By their nature, these forward-looking statements as well as those included in any other material discussed at any roadshow presentation involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future periperormance. A number of important factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. No one undertakes publicly to update or revise any such forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise.

Return targets are targets only and are based over the long-term on the performance projections of the investment strategy and market conditions at the time of modelling and are therefore subject to change. There is no guarantee that any target return can be achieved. Investors should not place any reliance on such target return in deciding whether to invest in Ilika.

To the extent available, the industry, market and competitive position data contained in these materials come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. The contents of this document have not been independently verified, are not should not constitute a due diligence review and should not be construed as such. No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of Ilika or any of its directors, officers, employees, agents or advisers or any other person as to the accuracy, completeness or fairness of the information, forward-looking statements or opinions or in respect of any omission, and this document is distributed expressly on the basis that it shall not give rise to any liability or obligation if, for whatever reason, any of its contents are opported to recipient with access to additional information or to correct any inaccuracies herein which may become apparent.

The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to verification, completion and change without notice.

By attending the presentation you agree to be bound by the foregoing limitations.

NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. THIS COMMUNICATION IS DIRECTED ONLY AT PERSONS TO WHOM IT IS LAWFUL TO COMMUNICATE TO.

#### **Business overview**



#### Ilika is a pioneer in solid-state battery technology



#### **Highlight Summary**



- ✓ Implementation of Stereax ® thin film development programmes with five commercial partners:
  - Four industrial monitoring applications
  - One medical device
- Achieving record energy density from ultra-thin cells
  - Launching M50 cells, mm-scale miniature batteries
    - Establishing Stereax ® manufacturing collaboration with Semefab
      - Commencing two electric vehicle programmes with three leading automotive companies.

# **Stereax** ® Commercial Highlights



- Delivering a perpetual beacon for high value asset tagging
  - Developing a condition monitor for wind turbine blades
    - Designing a rail-track strain gauge
      - Designing an autonomous environmental sensor card
        - Dispatching batteries for evaluation in miniature medical implants

# **Stereax** ® **Development Partners**









Wind turbine condition monitoring



Track monitoring



Environmental monitoring

**Biomedical partner** 

Powering medical implants

#### **Goliath Commercial Highlights**



✓ Securing £4.2m of grant funding from the Faraday Battery Challenge to develop large format solid-state cells for automotive

✓ In Oct 2018 commencing PowerDrive Line collaboration for rapid charging

✓ In Feb 2019 starting MoSeSS collaboration led by McLaren for high-power performance vehicles.

#### **Goliath Development Partnerships**



# Goliath Development Programme:

- Establish Ilika as leader in development of manufacturing methods for production of solid state batteries
- Commercialise the large format solid state battery (Goliath)

POWER DRIVE LINE Innovate UK









MOSESS Innovate UK








Lead Partner Framework

# Stereax ® product evolution





#### **Technical Highlights**



▲ Achieving record energy density from ultra-thin cells for medical implants


Development of photolithographic methods to produce custom cells compatible with industrial processes

In April 2019, launch of mm-scale M50 cells for MedTech

✓ Demonstration of ability of P180 cells to withstand rapid ramps to high temperatures for industrial applications.


#### Stereax® road map





# Stereax ® product to market mapping






#### **Partner Engagement**



**Product Development** 



**Engineering Fees** 

**Technology Transfer** 



**License Fees** 


**Product Manufacturing** 




**Royalties** 

# Stereax ® manufacturing partnerships








#### Stereax® commercialisation







■ Evaluations in progress ■ R&D programs

NDA

■ Licensing & lead partner proposals

#### **Example ROI calculation**



#### Implantable blood pressure sensor

Income/ (costs) for Ilika	Yr 1	Yr2	Yr3	Yr5-10 p.a.
	\$k	\$k	\$k	\$k
Development costs	(500)	(250)		
Contribution to costs	350	175		
Licence issue fee		375	125	
Royalties				600
Total	(150)	300	125	600



▲ ROI 63% using 20% discount rate

- ✓ Volume 60,000 units p.a
- ✓ 10% royalty on \$100 battery cost



# Financial summary for the year ended 30<sup>th</sup> April 2019



✓ Turnover £2.6m

- (2018: £2.1m)
- Front end of large format battery developments
- Loss for the period £2.3m
- (2018: £2.9m)
- Staff costs remained level at £2.8m
- Placing and open offer in the year raised net £4.1m
  - 22.3m shares issued at 20p in July 2018
- **∠** Loss per share reduced to 2.4p (2018: 3.7p)
- Cash balance £4.0m

(2018: £2.8m)

# **Summary cash-flow to 30<sup>th</sup> April 2019**



	£m
Opening balance	2.8
Fundraise	4.1
Capex*	(1.0)
Operating cash outflow	(2.2)
R&D tax credit	0.3
Closing balance	4.0

<sup>\*</sup>New facility & equipment for large format battery development

#### 2019/20 Outlook



- Goliath programmes and autonomous sensor deployment to drive revenue growth (order book of £2.7m for 2019/20)
- Stereax ® manufacturing scale up
- ✓ Focus on converting OEM support into commercial revenue
- ✓ The Board looks forward to further growth in 2019/20



#### **Contact details**



- www.ilika.com
- @ilikaplc
- /ilika-plc





